Bosh sahifaBCRX • NASDAQ
add
BioCryst Pharmaceuticals Inc
10,24 $
Seans yopilganidan keyin:(0,78%)-0,080
10,16 $
Yopilgan:16-may, 19:12:39 (GMT-4) · USD · NASDAQ · Ogohlantirish
Yopilish kursi
10,21 $
Kunlik diapazon
10,12 $ - 10,38 $
Yillik diapazon
5,92 $ - 11,11 $
Bozor kapitalizatsiyasi
2,14 mlrd USD
Oʻrtacha hajm
5,75 mln
Narx/foyda
-
Dividend daromadliligi
-
Asosiy maydon
NASDAQ
Yangiliklarda
Moliyaviy axborot
Moliyaviy hisobot
Daromad
Sof foyda
| (USD) | mar, 2025info | Y/Y qiyosi |
|---|---|---|
Daromad | 145,53 mln | 56,89% |
Joriy xarajat | 82,47 mln | 38,62% |
Sof foyda | 32,00 ming | 100,09% |
Sof foyda marjasi | 0,02 | 100,05% |
Har bir ulushga tushum | 0,00 | 100,00% |
EBITDA | 21,56 mln | 252,01% |
Amaldagi soliq stavkasi | 95,78% | — |
Balans
Jami aktivlari
Jami passivlari
| (USD) | mar, 2025info | Y/Y qiyosi |
|---|---|---|
Naqd pul va qisqa investitsiyalar | 295,09 mln | -12,32% |
Jami aktivlari | 480,05 mln | 2,60% |
Jami passivlari | 931,97 mln | -1,28% |
Umumiy kapital | -451,93 mln | — |
Tarqatilgan aksiyalar | 209,25 mln | — |
Narxi/balansdagi bahosi | -4,73 | — |
Aktivlardan daromad | 10,94% | — |
Kapitaldan daromad | 14,29% | — |
Pul aylanmasi
Naqd pulning sof oʻzgarishi
| (USD) | mar, 2025info | Y/Y qiyosi |
|---|---|---|
Sof foyda | 32,00 ming | 100,09% |
Operatsiyalardan naqd pul | -27,52 mln | 48,74% |
Sarmoyadan naqd pul | 27,10 mln | -5,78% |
Moliyadan naqd pul | 529,00 ming | 150,48% |
Naqd pulning sof oʻzgarishi | 558,00 ming | 102,12% |
Boʻsh pul | -15,88 mln | 66,09% |
Haqida
BioCryst Pharmaceuticals, Inc. is an American pharmaceutical company headquartered in Durham, North Carolina. The company is a late stage biotech company that focuses on oral drugs for rare and serious diseases. BioCryst's antiviral drug peramivir was approved by FDA in December 2014. It has also been approved in Japan, Korea, and China. Wikipedia
Tashkil etilgan
1986
Sayt
Xodimlar soni
580
